[Hemorrhaging during pregnancy].
Hemorrhaging during pregnancy is often fulminant and life-threatening for mother and child. Of maternal deaths occurring during pregnancy, 25% are caused by hemorrhaging. All physicians involved in the interdisciplinary treatment of hemorrhaging during pregnancy need to be familiar with the specific pathophysiology of hemostatic changes during pregnancy, e.g. elevated hemostatic capacity, reduced anti-coagulation activity and severe alterations of the fibrinolysis system. Therapists must be able to perform a consequent, goal-directed interdisciplinary approach to prevent adverse maternal and fetal outcomes. The major issues of therapy are causal obstetric treatment of the bleeding, early detection and therapy of hyperfibrinolysis, optimization of fibrinogen and platelet levels and knowledge of the possibilities of a targeted coagulation therapy.
Hofer
S
S
Klinik für Anästhesiologie, Universitätsklinikum Heidelberg, Heidelberg. stefan.hofer@med.uni-heidelberg.de
Schreckenberger
R
R
Heindl
B
B
Görlinger
K
K
Lier
H
H
Maul
H
H
Martin
E
E
Weigand
M A
MA
D000328:Adult; D015942:Factor VIIa / Q000627:therapeutic use; D005260:Female; D005342:Fibrinolysis / Q000502:physiology; D006470:Hemorrhage / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D010922:Placenta Diseases / Q000503:physiopathology / Q000628:therapy; D017713:Platelet Transfusion; D006473:Postpartum Hemorrhage / Q000503:physiopathology / Q000628:therapy; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*
D015942:Factor VIIa